Google Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Google Inc trades at $348.1 (market cap $4.24T), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: Google Inc is far larger — about 337× Halozyme Therapeutics Inc. Common Stock's market cap, and Google Inc pays a 0.26% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| GOOG | HALO | |
|---|---|---|
Market Cap | $4.24T | $12.58B |
Volume | 13,937,902 | 2,179,278 |
Sector | Media | Health |
52-Week High | $399.06 | $115.22 |
52-Week Low | $237.49 | $61.63 |
Typical Hold Time | 137 Days | 1 Days |
Enterprise Value | $4.13T | $14.49B |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.86, up 0.14% with strong technical momentum above key support levels. The stock shows robust fundamentals with revenue growth accelerating to $402.84B in 2025 and net income margins expanding to 32.8%. Recent earnings beats and a bullish analyst consensus at 87% buy ratings support the positive outlook, though elevated capital expenditures and regulatory scrutiny present near-term headwinds.
Alphabet's outlook remains favorable with AI-driven cloud growth and consistent earnings outperformance. The stock trades at a reasonable 17.3 P/E with 34% upside to the $435.24 consensus target. Key risks include massive AI infrastructure spending impacting cash flow and ongoing regulatory litigation. The technical setup suggests continued momentum toward resistance at $352-$354.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →